Holdings: Gynäkologische Malignome

Gynäkologische Malignome: Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen

Saved in:

Bibliographic Details
Format:	Book
Language:	German
Published:	München [i.e.] Germering Zuckschwerdt 2012
Edition:	10., überarb. und erw. Aufl.
Subjects:	Gynäkologische Onkologie Therapie Frau Nachsorge Krebs > Medizin
Online Access:	Inhaltsverzeichnis
Physical Description:	XVI, 271 S.
ISBN:	9783886039999 3886039994

Staff View

MARC


LEADER	00000nam a2200000 c 4500
001	BV039807742
003	DE-604
005	20131024
007	t
008	120116s2012 \|\|\|\| 00\|\|\| ger d
015			\|a 11,N23 \|2 dnb
016	7		\|a 1012159817 \|2 DE-101
020			\|a 9783886039999 \|c Pb. : ca. EUR 29.90 (DE) \|9 978-3-88603-999-9
020			\|a 3886039994 \|c Pb. : ca. EUR 29.90 (DE) \|9 3-88603-999-4
024	3		\|a 9783886039999
035			\|a (OCoLC)774095491
035			\|a (DE-599)DNB1012159817
040			\|a DE-604 \|b ger \|e rakwb
041	0		\|a ger
049			\|a DE-19 \|a DE-12 \|a DE-578
082	0		\|a 616.99465 \|2 22//ger
084			\|a XH 8200 \|0 (DE-625)152953:13129 \|2 rvk
084			\|a WP 145 \|2 nlm
084			\|a 610 \|2 sdnb
245	1	0	\|a Gynäkologische Malignome \|b Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen \|c W. Kuhn ... (Hrsg.)
250			\|a 10., überarb. und erw. Aufl.
264		1	\|a München [i.e.] Germering \|b Zuckschwerdt \|c 2012
300			\|a XVI, 271 S.
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
650	0	7	\|a Gynäkologische Onkologie \|0 (DE-588)4022657-8 \|2 gnd \|9 rswk-swf
650	0	7	\|a Therapie \|0 (DE-588)4059798-2 \|2 gnd \|9 rswk-swf
650	0	7	\|a Frau \|0 (DE-588)4018202-2 \|2 gnd \|9 rswk-swf
650	0	7	\|a Nachsorge \|0 (DE-588)4041071-7 \|2 gnd \|9 rswk-swf
650	0	7	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|2 gnd \|9 rswk-swf
689	0	0	\|a Gynäkologische Onkologie \|0 (DE-588)4022657-8 \|D s
689	0	1	\|a Therapie \|0 (DE-588)4059798-2 \|D s
689	0		\|5 DE-604
689	1	0	\|a Gynäkologische Onkologie \|0 (DE-588)4022657-8 \|D s
689	1	1	\|a Nachsorge \|0 (DE-588)4041071-7 \|D s
689	1		\|5 DE-604
689	2	0	\|a Frau \|0 (DE-588)4018202-2 \|D s
689	2	1	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|D s
689	2	2	\|a Therapie \|0 (DE-588)4059798-2 \|D s
689	2		\|8 1\p \|5 DE-604
689	3	0	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|D s
689	3	1	\|a Nachsorge \|0 (DE-588)4041071-7 \|D s
689	3	2	\|a Frau \|0 (DE-588)4018202-2 \|D s
689	3		\|8 2\p \|5 DE-604
700	1		\|a Kuhn, Walther \|d 1960- \|e Sonstige \|0 (DE-588)1043327347 \|4 oth
856	4	2	\|m DNB Datenaustausch \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024668099&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
999			\|a oai:aleph.bib-bvb.de:BVB01-024668099
883	1		\|8 1\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk
883	1		\|8 2\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk

Record in the Search Index

_version_	1804148738261778432
adam_text	INHALT GELEITWORT ......................................................................................................... V VORWORT ........................................................................................................... VII HERAUSGEBER UND AUTOREN ................................................................................... IX ALLGEMEINER TEIL GRUNDLAGEN DER TUMORTHERAPIE ........................................................................ 2 LOKALE THERAPIE ............................................................................................... 3 - OPERATIVE THERAPIE ..................................................................................... 3 - STRAHLENTHERAPIE ....................................................................................... 3 - LOKAL DESTRUIERENDE VERFAHREN .................................................................. 5 SYSTEMISCHE TUMORTHERAPIE ............................................................................ 6 - HORMONTHERAPIE ......................................................................................... 7 - TARGETED THERAPIE ..................................................................................... 9 - ZYTOSTATIKATHERAPIE ................................................................................... 10 ABRECHNUNG ONKOLOGISCHER LEISTUNGEN ........................................................... 24 SUPPORTIVTHERAPIE ............................................................................................ 27 HAEMATOTOXIZITAET ............................................................................................... 27 UEBELKEIT UND ERBRECHEN .................................................................................. 29 DIARRHOE ............................................................................................................. 32 OBSTIPATION ....................................................................................................... 32 STOMATITIS ......................................................................................................... 32 FATIGUE ............................................................................................................. 34 NEUROPATHIE ..................................................................................................... 35 HAUTVERAENDERUNGEN ........................................................................................ 35 KARDIOTOXIZITAET ...................................................... 37 PARAVASATE ....................................................................................................... 38 - ALLGEMEINE UND SPEZIELLE MASSNAHMEN BEI PARAVASATEN ........................... 39 ALLERGISCHE REAKTIONEN .................................................................................... 40 FEBRILE NEUTROPENIE, FIEBER UNTER CHEMOTHERAPIE .......................................... 41 TUMORLYSE-SYNDROM (TLS) .............................................................................. 44 HYPERKALZAEMIE/HYPERKALZAEMISCHE KRISE ......................................................... 45 FLUID-RETENTION-SYNDROM/MALIGNE ERGUESSE .................................................. 46 - MALIGNER PLEURAERGUSS ................................................................................ 46 - MALIGNER ASZITES ........................................................................................ 46 - MALIGNER PERIKARDERGUSS ........................................................................... 48 THROMBEMBOLISCHE EREIGNISSE .......................................................................... 48 ZENTRALNERVOESE KOMPLIKATIONEN ...................................................................... 49 - HIRNOEDEM ..................................................................................................... 49 - RUECKENMARKKOMPRESSION ........................................................................... 50 PATHOLOGISCHE FRAKTUREN .................................................................................. 50 NIERENINSUFFIZIENZ ........................................................................................... 51 ILEUS .................................................................................................................. 51 VENA-CAVA-SUPERIOR-SYNDROM (VCSS)/OBERE EINFLUSSSTAUUNG ....................... 52 SCHMERZTHERAPIE BEI MALIGNEN TUMOREN ....................................................... 54 PSYCHOONKOLOGIE ............................................................................................. 62 SOZIALE REHABILITATION ...................................................................................... 65 PHYSIKALISCHE THERAPIE UND SPORT ................................................................... 66 - SPORTLICHE BETAETIGUNG ................................................................................ 67 - SPORTLICHE BETAETIGUNG IM METASTASIERTEN STADIUM .................................... 69 LYMPHOEDEM ..................................................................................................... 70 - THERAPIE DES LYMPHOEDEMS .......................................................................... 71 TUMORNACHSORGE ............................................................................................... 74 ERLAEUTERUNGEN ZUM NACHSORGEPROGRAMM BEIM MAMMAKARZINOM ................. 75 - ANAMNESE .................................................................................................. 78 - KOERPERLICHE UNTERSUCHUNG ......................................................................... 78 - LABOR/APPARATIVE DIAGNOSTIK ..................................................................... 78 ERLAEUTERUNGEN ZUM NACHSORGEPROGRAMM BEI GENITALKARZINOMEN ................. 79 - ANAMNESE ................................................................................................... 79 - KOERPERLICHE UNTERSUCHUNG .......................................................................... 79 - LABOR/APPARATIVE DIAGNOSTIK ...................................................................... 79 KOMPLEMENTAERMEDIZIN ..................................................................................... 81 MALIGNOME IN DER SCHWANGERSCHAFT ............................................................... 86 DIAGNOSTIK IN DER SCHWANGERSCHAFT ................................................................. 87 SYSTEMTHERAPIE ................................................................................................. 87 ENTBINDUNGSMODUS .......................................................................................... 88 OPERATION ......................................................................................................... 88 - MAMMAKARZINOM ........................................................................................ 88 - OVARIALNEOPLASIEN ...................................................................................... 89 - ZERVIXKARZINOM .......................................................................................... 90 - SELTENE FAELLE .............................................................................................. 91 TUMORMARKER ................................................................................................... 94 STRAHLENTHERAPIE ............................................................................................... 94 PSYCHOLOGISCHE UNTERSTUETZUNG ....................................................................... 94 SCHWANGERSCHAFT NACH MAMMAKARZINOM ....................................................... 94 SCHWANGERSCHAFT NACH GYNAEKOLOGISCHEN MALIGNOMEN .................................. 95 - ZERVIXKARZINOM ........................................................................................ 95 - ENDOMETRIUMKARZINOM ............................................................................. 95 FERTILITAETSERHALT ................................................................................................. 96 - GNRH ........................................................................................................... 96 - KRYOKONSERVIERUNG ................................................................................... 97 SPEZIELLER TEIL MAMMAKARZINOM ............................................................................................ 102 EPIDEMIOLOGIE ................................................................................................... 102 PROGNOSEFAKTOREN ............................................................................................ 102 DIAGNOSTIK ....................................................................................................... 104 PATHOMORPHOLOGIE .......................................................................................... 105 - NICHT INVASIVE KARZINOME ......................................................................... 105 - INVASIVE KARZINOME ................................................................................... 109 OPERATIVE THERAPIE DES PRIMAEREN MAMMAKARZINOMS ...................................... 112 - PLASTISCHE CHIRURGIE DER BRUST ................................................................... 115 ADJUVANTE STRAHLENTHERAPIE ............................................................................ 117 - DUKTALES CARCINOMA IN SITU ....................................................................... 117 - LOBULAERES CARCINOMA IN SITU ..................................................................... 117 - INVASIVES KARZINOM ................................................................................. 117 ADJUVANTE HORMON UND CHEMOTHERAPIE ....................................................... 119 - METAANALYSEN DER EBCTCG ......................................................................... 120 - ENDOKRINE THERAPIE ................................................................................... 121 - CHEMOTHERAPIE ............................................................................................ 124 ANTIKOERPERTHERAPIE MIT TRASTUZUMAB ............................................................. 128 BISPHOSPHONATE .............................................................................................. 129 THERAPIE DES LOKOREGIONAEREN REZIDIVS ............................................................. 130 PALLIATIVE THERAPIE .......................................................................................... 131 - HORMONELLE THERAPIE ................................................................................. 133 - CHEMOTHERAPIE .......................................................................................... 135 - NEUE THERAPIEFORMEN IN DER METASTASIERTEN SITUATION ............................. 137 - BISPHOSPHONATE .......................................................................................... 137 SONDERFAELLE ....................................................................................................... 141 - FAMILIAERES MAMMAKARZINOM ..................................................................... 141 - INFLAMMATORISCHES MAMMAKARZINOM ...................................................... 142 - PAGET-KARZINOM DER MAMMA ................................................................... 143 - BEIDSEITIGES MAMMAKARZINOM ................................................................... 143 - MAMMAKARZINOM UND SCHWANGERSCHAFT .................................................. 144 - CYSTOSARCOMA PHYLLOIDES MAMMAE ........................................................... 144 OVARIALMALIGNOME ........................................................................................... 150 KLASSIFIZIERUNG DER HAEUFIGSTEN OVARIALTUMOREN NACH FIGO UND WHO ........... 150 INVASIVES OVARIALKARZINOM .............................................................................. 150 - HAEUFIGKEIT ................................................................................................... 151 - UEBERLEBENSRATEN .......................................................................................... 151 - STADIENEINTEILUNG ........................................................................................ 152 - SCREENING ..................................................................................................... 153 - PRAEOPERATIVE DIAGNOSTIK .............................................................................. 154 - OPERATIVE THERAPIE ...................................................................................... 156 - OPERATIVE FOLGEEINGRIFFE ............................................................................ 161 - SONDERFAELLE ................................................................................................. 165 - MEDIKAMENTOESE THERAPIE ........................................................................... 166 - STRAHLENTHERAPIE ........................................................................................ 177 - HORMONTHERAPIE .......................................................................................... 178 - ANTIKOERPERTHERAPIE UND TYROSINKINASEINHIBITOREN ................................... 178 - IMMUNTHERAPIE .......................................................................................... 179 PRIMAER PAPILLAER SEROESES KARZINOM DES PERITONEUMS (PSCP) ........................... 179 TUBENKARZINOM ............................................................................................... 179 - HAEUFIGKEIT ................................................................................................... 180 - UEBERLEBENSRATE ............................................................................................. 180 - PRIMAERTHERAPIE ............................................................................................. 180 BORDERLINE-TUMOREN ........................................................................................ 180 - MIKROINVASION ............................................................................................ 181 - MIKROPAPILLAERES WACHSTUM ......................................................................... 181 - EXTRAOVARIELLE HERDE .................................................................................. 182 - NICHT INVASIVE HERDE UND INVASIVE HERDE IM PERITONEUM UND OMENTUM . 182 - LYMPHKNOTENBETEILIGUNG ........................................................................... 182 - OPERATIONSZIEL ............................................................................................ 182 - HISTOPATHOLOGISCHE BEURTEILUNG ................................................................. 183 - FERTILITAETSERHALTENDE OPERATION ................................................................... 184 - CHEMOTHERAPIE ............................................................................................ 184 - REZIDIVTHERAPIE .......................................................................................... 184 NICHTEPITHELIALE OVARIALMALIGNOME ................................................................. 189 - KEIMZELLTUMOREN ........................................................................................ 189 - KEIMSTRANGSTROMATUMOREN ......................................................................... 197 - SARKOME DES OVARS ...................................................................................... 202 ENDOMETRIUMKARZINOM .................................................................................... 204 EPIDEMIOLOGIE ................................................................................................... 205 STAGING ............................................................................................................. 205 CHIRURGIE ......................................................................................................... 206 - INTRAOPERATIVE MAKROSKOPISCHE UTERINE BEGUTACHTUNG UND SCHNELLSCHNITTUNTERSUCHUNG ....................................................................... 208 - PELVINE UND PARAAORTALE LYMPHONODEKTOMIE ............................................ 209 ADJUVANTE THERAPIE ........................................................................................ 210 - POSTOPERATIVE STRAHLENTHERAPIE ................................................................. 210 - CHEMOTHERAPIE ............................................................................................ 211 - ENDOKRINE THERAPIE .................................................................................... 212 PRIMAERE STRAHLENTHERAPIE ................................................................................ 212 THERAPIE DES REZIDIVS ...................................................................................... 213 - THERAPIE DES LOKOREGIONAEREN REZIDIVS ....................................................... 213 - THERAPIE BEI METASTASIERUNG ..................................................................... 213 ABWEICHUNG VOM STANDARD: DIE JUNGE PATIENTIN ............................................ 214 - OVARERHALTUNG BEI DER PRAEMENOPAUSALEN PATIENTIN .................................... 214 - LYNCH-SYNDROM .......................................................................................... 215 UTERINE SARKOME UND MISCHTUMOREN ............................................................... 219 ALLGEMEINES ..................................................................................................... 219 MALIGNE TUMOREN DES ENDOMETRIALEN STROMAS (STROMASARKOME) ................... 220 - ENDOMETRIALES STROMASARKOM ..................................................................... 221 - UNDIFFERENZIERTES ENDOMETRIALES SARKOM ................................................... 223 LEIOMYOSARKOM .............................................................................................. 224 GEMISCHTE EPITHELIALE/MESENCHYMALE TUMOREN (MUELLER-MISCHTUMOREN, MESODERMALE MISCHTUMOREN) ......................................................................... 226 - KARZINOSARKOM (MALIGNER MUELLER-MISCHTUMOR) ........................................ 226 GESTATIONELLE UND NICHT GESTATIONELLE TROPHOBLASTERKRANKUNGEN ................... 231 DEFINITION ......................................................................................................... 231 WHO-KLASSIFIKATION ........................................................................................ 231 VILLOESE TROPHOBLASTERKRANKUNGEN ................................................................... 233 - PARTIALMOLE ................................................................................................ 233 - BLASENMOLE (SYNONYM: KOMPLETTE MOLE) .................................................. 234 - INVASIVE BLASENMOLE .................................................................................. 235 NICHT VILLOESE TROPHOBLASTERKRANKUNGEN (NVTE) ............................................ 236 - CHORIONKARZINOM ........................................................................................ 236 - PLAZENTABETTKNOETCHEN (PLACENTAL SITE NODULE, PSN) .................................... 238 - HYPERPLASTISCHE IMPLANTATIONSSTELLE (EXAGGERATED PLACENTAL SITE, EPS) ... 238 - PLACENTABETT-TUMOR (PLACENTAL SITE TROPHOBLASTIC TUMOR, PSTT) ............... 239 - EPITHELOIDER TROPHOBLASTTUMOR (ETT) ......................................................... 240 NICHT GESTATIONELLE TROPHOBLASTERKRANKUNGEN ................................................. 240 ZERVIXKARZINOM ............................................................................................... 242 HAEUFIGKEIT ......................................................................................................... 242 RISIKOFAKTOREN ................................................................................................. 242 UEBERLEBENSRATE ................................................................................................. 244 DIAGNOSTIK ....................................................................................................... 244 THERAPIEPRINZIPIEN ........................................................................................... 245 OPERATION ......................................................................................................... 246 RADIOCHEMOTHERAPIE ........................................................................................ 250 CHEMOTHERAPIE ................................................................................................. 251 OPERATIVE THERAPIE BEI REZIDIV ........................................................................ 252 VULVAKARZINOM ................................................................................................. 254 HAEUFIGKEIT ......................................................................................................... 254 UEBERLEBENSRATE ................................................................................................. 254 KLINIK UND DIAGNOSTIK ...................................................................................... 255 PRIMAERTHERAPIE .................................................................................. 256 STRAHLENTHERAPIE ............................................................................................... 258 THERAPIE DES LOKOREGIONAEREN REZIDIVS ............................................................. 258 THERAPIE BEI FERNMETASTASIERUNG ................................................................... 259 VAGINALKARZINOM ............................................................................................. 260 HAEUFIGKEIT ......................................................................................................... 260 UEBERLEBENSRATE .................. 260 DIAGNOSTIK ....................................................................................................... 260 PRIMAERTHERAPIE ................................................................................................. 261 THERAPIE DES LOKOREGIONAEREN REZIDIVS ............................................................. 262 THERAPIE BEI FERNMETASTASIERUNG ................................................................... 262 STICHWORTVERZEICHNIS ...................................................................................... 264
any_adam_object	1
author_GND	(DE-588)1043327347
building	Verbundindex
bvnumber	BV039807742
classification_rvk	XH 8200
ctrlnum	(OCoLC)774095491 (DE-599)DNB1012159817
dewey-full	616.99465
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.99465
dewey-search	616.99465
dewey-sort	3616.99465
dewey-tens	610 - Medicine and health
discipline	Medizin
edition	10., überarb. und erw. Aufl.
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02525nam a2200625 c 4500</leader><controlfield tag="001">BV039807742</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20131024 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">120116s2012 \|\|\|\| 00\|\|\| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">11,N23</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1012159817</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783886039999</subfield><subfield code="c">Pb. : ca. EUR 29.90 (DE)</subfield><subfield code="9">978-3-88603-999-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3886039994</subfield><subfield code="c">Pb. : ca. EUR 29.90 (DE)</subfield><subfield code="9">3-88603-999-4</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783886039999</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)774095491</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1012159817</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99465</subfield><subfield code="2">22//ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 8200</subfield><subfield code="0">(DE-625)152953:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WP 145</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gynäkologische Malignome</subfield><subfield code="b">Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen</subfield><subfield code="c">W. Kuhn ... (Hrsg.)</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">10., überarb. und erw. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München [i.e.] Germering</subfield><subfield code="b">Zuckschwerdt</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 271 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gynäkologische Onkologie</subfield><subfield code="0">(DE-588)4022657-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Frau</subfield><subfield code="0">(DE-588)4018202-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nachsorge</subfield><subfield code="0">(DE-588)4041071-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Gynäkologische Onkologie</subfield><subfield code="0">(DE-588)4022657-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Gynäkologische Onkologie</subfield><subfield code="0">(DE-588)4022657-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Nachsorge</subfield><subfield code="0">(DE-588)4041071-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Frau</subfield><subfield code="0">(DE-588)4018202-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Nachsorge</subfield><subfield code="0">(DE-588)4041071-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="2"><subfield code="a">Frau</subfield><subfield code="0">(DE-588)4018202-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuhn, Walther</subfield><subfield code="d">1960-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1043327347</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024668099&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-024668099</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection>
id	DE-604.BV039807742
illustrated	Not Illustrated
indexdate	2024-07-10T00:11:54Z
institution	BVB
isbn	9783886039999 3886039994
language	German
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-024668099
oclc_num	774095491
open_access_boolean
owner	DE-19 DE-BY-UBM DE-12 DE-578
owner_facet	DE-19 DE-BY-UBM DE-12 DE-578
physical	XVI, 271 S.
publishDate	2012
publishDateSearch	2012
publishDateSort	2012
publisher	Zuckschwerdt
record_format	marc
spelling	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen W. Kuhn ... (Hrsg.) 10., überarb. und erw. Aufl. München [i.e.] Germering Zuckschwerdt 2012 XVI, 271 S. txt rdacontent n rdamedia nc rdacarrier Gynäkologische Onkologie (DE-588)4022657-8 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Frau (DE-588)4018202-2 gnd rswk-swf Nachsorge (DE-588)4041071-7 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Gynäkologische Onkologie (DE-588)4022657-8 s Therapie (DE-588)4059798-2 s DE-604 Nachsorge (DE-588)4041071-7 s Frau (DE-588)4018202-2 s Krebs Medizin (DE-588)4073781-0 s 1\p DE-604 2\p DE-604 Kuhn, Walther 1960- Sonstige (DE-588)1043327347 oth DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024668099&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk
spellingShingle	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen Gynäkologische Onkologie (DE-588)4022657-8 gnd Therapie (DE-588)4059798-2 gnd Frau (DE-588)4018202-2 gnd Nachsorge (DE-588)4041071-7 gnd Krebs Medizin (DE-588)4073781-0 gnd
subject_GND	(DE-588)4022657-8 (DE-588)4059798-2 (DE-588)4018202-2 (DE-588)4041071-7 (DE-588)4073781-0
title	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen
title_auth	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen
title_exact_search	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen
title_full	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen W. Kuhn ... (Hrsg.)
title_fullStr	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen W. Kuhn ... (Hrsg.)
title_full_unstemmed	Gynäkologische Malignome Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen W. Kuhn ... (Hrsg.)
title_short	Gynäkologische Malignome
title_sort	gynakologische malignome tumortherapie und nachsorge bei mamma und genitalmalignomen
title_sub	Tumortherapie und Nachsorge bei Mamma- und Genitalmalignomen
topic	Gynäkologische Onkologie (DE-588)4022657-8 gnd Therapie (DE-588)4059798-2 gnd Frau (DE-588)4018202-2 gnd Nachsorge (DE-588)4041071-7 gnd Krebs Medizin (DE-588)4073781-0 gnd
topic_facet	Gynäkologische Onkologie Therapie Frau Nachsorge Krebs Medizin
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024668099&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT kuhnwalther gynakologischemalignometumortherapieundnachsorgebeimammaundgenitalmalignomen

Holdings

There is no print copy available.

Interlibrary loan Place Request Caution: Not in THWS collection! Indexes

MARC

Record in the Search Index

There is no print copy available.

Similar Items